

Vincent Meininger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5353793/publications.pdf>

Version: 2024-02-01

40
papers

1,454
citations

361413

20
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

1794
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of a modular ontology and a semantic annotation tool to describe the care pathway of patients with amyotrophic lateral sclerosis in a coordination network. PLoS ONE, 2021, 16, e0244604.	2.5	1
2	Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurology, The, 2016, 15, 1217-1227.	10.2	65
3	Coordinated care affects hospitalization and prognosis in amyotrophic lateral sclerosis: a cohort study. BMC Health Services Research, 2015, 15, 134.	2.2	22
4	Radiation Therapy for Hypersalivation: A Prospective Study in 50 Amyotrophic Lateral Sclerosis Patients. International Journal of Radiation Oncology Biology Physics, 2014, 88, 589-595.	0.8	44
5	New therapy options for amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2013, 14, 1907-1917.	1.8	19
6	Improving survival in a large French ALS center cohort. Journal of Neurology, 2012, 259, 1788-1792.	3.6	33
7	How can we improve clinical trials in amyotrophic lateral sclerosis?. Nature Reviews Neurology, 2011, 7, 650-654.	10.1	49
8	ALS, what new 144 years after Charcot?. Archives Italiennes De Biologie, 2011, 149, 29-37.	0.4	11
9	Progression in ALS is not linear but is curvilinear. Journal of Neurology, 2010, 257, 1713-1717.	3.6	124
10	Brain and Plasma Riluzole Pharmacokinetics: Effect of Minocycline Combination. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 209.	2.1	35
11	Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trial. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 378-383.	2.1	83
12	Management of Amyotrophic Lateral Sclerosis. Drugs, 2008, 68, 1037-1048.	10.9	37
13	Lithium therapy in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 122-122.	2.1	9
14	Causes of death in a post-mortem series of ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 59-62.	2.1	140
15	Brain perfusion imaging in amyotrophic lateral sclerosis: Extent of cortical changes according to the severity and topography of motor impairment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 9-15.	2.1	24
16	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 217-223.	2.1	98
17	Treatment of emotional lability in ALS. Lancet Neurology, The, 2005, 4, 70.	10.2	9
18	Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2005, 2, 166-176.	1.4	88

#	ARTICLE	IF	CITATIONS
19	Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?. <i>Neurodegenerative Diseases</i> , 2005, 2, 208-214.	1.4	15
20	Xaliproden in amyotrophic lateral sclerosis: early clinical trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 99-106.	1.2	24
21	European ALS Consortium. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 133-134.	1.2	2
22	Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 107-117.	1.2	104
23	Survival endpoint: Summary. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2002, 3, S41-S44.	1.2	2
24	Clinical trials: the past, a lesson for the future. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2001, 2, 15-18.	1.2	3
25	Modifications of tubulin heterogeneity during embryonic and postnatal stages in a specific region of mouse brain. <i>Brain Research</i> , 1991, 548, 133-139.	2.2	2
26	Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. <i>International Journal of Cancer</i> , 1990, 46, 262-266.	5.1	107
27	Characteristics of Microtubules at the Different Stages of Neuronal Differentiation and Maturation. <i>International Review of Cytology</i> , 1989, 114, 21-79.	6.2	20
28	Biochemical basis of microtubule cold stability in the peripheral and central nervous systems. <i>Brain Research</i> , 1988, 450, 231-236.	2.2	16
29	Modifications of tubulin heterogeneity during axonal growth in the embryonic nervous system. <i>Developmental Brain Research</i> , 1988, 38, 296-299.	1.7	5
30	Spatial organization of microtubules in various types of cells in the embryonic tectal plate of mouse using immunofluorescence after PEG embedding. <i>Biology of the Cell</i> , 1988, 64, 301-308.	2.0	4
31	Ciliogenesis and centriole formation in the mouse embryonic nervous system. An ultrastructural analysis. <i>Biology of the Cell</i> , 1988, 62, 165-169.	2.0	21
32	In situ appearance of the cold-stable microtubules in the growing axons of the tectal plate of mouse investigated immunocytochemically after polyethyleneglycol (PEG) embedding. <i>Developmental Brain Research</i> , 1987, 36, 171-180.	1.7	11
33	Heterogeneity of cold-stable and cold-labile tubulin in axon- and soma-enriched portions of the adult mouse brain. <i>Neuroscience Letters</i> , 1987, 77, 166-170.	2.1	9
34	The loss of motoneurons corresponding to specific muscles in the wobbler mutant mouse. <i>Neuroscience Letters</i> , 1983, 37, 99-104.	2.1	41
35	Histogenesis of the inferior colliculus in rat. <i>Anatomy and Embryology</i> , 1982, 165, 19-37.	1.5	16
36	Organisation des motoneurones des muscles pectoraux chez le rat. <i>Cells Tissues Organs</i> , 1981, 109, 209-217.	2.3	20

#	ARTICLE	IF	CITATIONS
37	Postnatal modifications of the dendritic tree of cells in the inferior colliculus of the cat. A quantitative Golgi analysis. <i>Journal of Comparative Neurology</i> , 1981, 200, 339-355.	1.6	35
38	Bases anatomiques de la mémoire. <i>Anatomia Clinica Französische Ausgabe</i> , 1980, 2, 275-282.	0.1	0
39	BILATERAL TACTILE APHASIA: A TACTO-VERBAL DYSFUNCTION. <i>Brain</i> , 1978, 101, 381-401.	7.6	95
40	The cytoarchitecture of the inferior colliculus in the cat. <i>Journal of the Neurological Sciences</i> , 1977, 34, 25-36.	0.6	7